Most Recent
ACCC boss Rod Sims has won a five-year extension of his term as Chair, ensuring the high energy regulator will continue to make good on its promises of higher fines and tougher enforcement of the nation's competition and consumer laws.
Scenic Tours has won a major victory on appeal in a class action against a ruling that put it on the hook for claims that luxury European river cruise passengers were owed damages and compensation after they were forced to take the bus because of flood waters.
A judge has found an Aboriginal art and souvenir supplier misled consumers by creating the false impression its products were made in Australia by Indigenous people, when they were actually made in Indonesia, the consumer watchdog said Wednesday.
The judge overseeing a class action against American Medical Systems over allegedly defective pelvic mesh implants has rejected the medical device maker's bid to alter the start date for a sub-group of class members.
H.J. Heinz Company has dropped its appeal of a ruling that it marketed its sugary snacks to kids as healthy, after the ACCC won a fraction of the $10 million fine it sought for the consumer law violations.
The Australian Competition and Consumer Commission has successfully escaped a lawsuit by a Chinese vitamin company Nature's Care after arguing it had been wrongly "dragged" into the case.
Bannister Law has withdrawn from a class action it filed against Ford over allegedly defective Powershift transmissions following a dispute between the firm and the litigation funder that's backing the case.
Cash Converters has reached a settlement on the eve of trial in one of two consumer class actions alleging it engaged in unconscionable conduct by imposing high interest rates on short-term loans.
ASIC has successfully opposed a Federal Court judge's push to appoint an independent referee in its case against AMP Financial Planning over alleged insurance churning.
The High Court has dismissed the ACCC's bid to appeal a Full Federal Court decision upholding a ruling that drug giant Pfizer did not misuse its market power in the months leading up to the expiration of the patent for its blockbuster cholesterol drug Lipitor.